3-(piperidin-4-yl)-isoxazol-3(oh)-ones for treatment of dermatologic disorders

A compound of Formula 1,

• wherein
• R1 and R2 are each selected from the group consisting of hydrogen, deuterium, aryl, hetero aryl, C1-C8 alkyl, optionally being substituted with one or more substituents independently being R3, and a 3-10 membered ring formed by R1 and R2 optionally comprising a selected element selected from the group consisting of O and N and optionally substituted with a C1-C10 alkyl or aryl, hetero aryl optional substituted with R3;
• R3 is selected from the group consisting of an aryl, hetero aryl, fluorine(s), a C1-C6 alkyl containing one or more fluorines, a C1-C6 alkyl containing one or more deuterium, a C1-C6 alkyl containing hydroxy, the aryl and heteroaryl optionally being substituted with one or more halogen, a fluorinated alkoxy, a fluorinated alkyl, a sulfonyl, one or more deuterium, a C1-C6 alkyl, a C1-C6 alkoxy, a nitrile, and a C1-C6 alkyl optionally substituted with one or more groups selected from the group consisting of COOR4, OCOR4, CONR5R6, NR5COR6 and OR4;
• wherein R4 is a C1-C10 alkyl optionally substituted with one or more fluorine, deuterium, alkoxy, arylcarboxylate, alkyl carboxylate;
• R5 and R6 are selected from the group consisting of hydrogen, alkyl and a 4-8 membered carbon ring formed by R5 and R6;
• and including pharmaceutically suitable salts, hydrates or solvates thereof, for use in the treatment of a dermatological disorder.